Data characterizing the biophysical and nitric oxide release properties of the tDodSNO – Styrene maleic anhydride nanoparticle SMA-tDodSNO
Houman Alimoradi,
Anita Barzegar-Fallah,
Ivan A. Sammut,
Khaled Greish,
Gregory I. Giles
Affiliations
Houman Alimoradi
Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand
Anita Barzegar-Fallah
Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand
Ivan A. Sammut
Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand
Khaled Greish
College of Medicine and Medical Sciences, Department of Molecular Medicine and Nanomedicine Unit, Princess Al-Jawhara Center for Molecular Medicine and Inherited Disorders, Arabian Gulf University, Manama, Bahrain,
Gregory I. Giles
Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand; Corresponding author.
Nitric oxide (NO) donor drugs have a range of clinical applications, and are also being developed as therapeutics for the potential treatment of multiple diseases. This article presents data describing the synthesis and characterisation of a novel NO releasing nanoparticle formed by encapsulation of the NO donor tDodSNO into a co-polymer of styrene and maleic acid (SMA) to afford SMA-tDodSNO. The pharmacological activity of SMA-tDodSNO is discussed in our accompanying manuscript “Encapsulation of tDodSNO generates a photoactivated nitric oxide releasing nanoparticle for localized control of vasodilation and vascular hyperpermeability”. (Alimoradio et al. [1]).
